Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167724 | 0.95 | LTA4H (0.74) | LTA4HKCNH2HRH3TLR9 | |
| SCHEMBL4965130 | 0.92 | LTA4H (0.72) | LTA4HKCNH2HRH3TLR9 | |
| SCHEMBL2167826 | 0.87 | LTA4H (0.80) | LTA4HKCNH2HRH3TLR9 | |
| SCHEMBL2168682 | 0.87 | LTA4H (1.00) | LTA4HKCNH2TLR9 | |
| SCHEMBL2169707 | 0.86 | LTA4H (0.58) | LTA4HKCNH2HRH3 | |
| SCHEMBL2168147 | 0.86 | LTA4H (0.78) | LTA4HKCNH2HRH3 | |
| SCHEMBL2169516 | 0.86 | LTA4H (1.00) | LTA4HKCNH2TLR9 | |
| SCHEMBL2168051 | 0.86 | LTA4H (0.95) | LTA4HKCNH2TLR9 | |
| SCHEMBL2170260 | 0.85 | LTA4H (1.00) | LTA4HKCNH2HRH3TLR9 | |
| SCHEMBL2170316 | 0.85 | LTA4H (1.00) | LTA4HKCNH2TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4726238-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | claimed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | LTA4H 1/4885KCNH2 3429/4885HRH3 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.